DOI: 10.1128/CMR.00043-19
SUMMARY
Hosts with compromised or naive immune systems, such as individuals living with HIV/AIDS, transplant recipients, and fetuses, are at the highest risk for complications from cytomegalovirus (CMV) infection. Despite substantial progress in prevention, diagnostics, and treatment, CMV continues to negatively impact both solid-organ transplant (SOT) and hematologic cell transplant (HCT) recipients. In this article, we summarize important developments in the field over the past 10 years and highlight new approaches and remaining challenges to the optimal control of CMV infection and disease in transplant settings.
FOOTNOTES
- Published 28 October 2020.
Supplemental material is available online only.
- Copyright © 2020 American Society for Microbiology.
Log in using your username and password
Log in through your institution
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
- Top
- Article
- SUMMARY
- INTRODUCTION
- DIAGNOSTICS
- PREVENTION: STRATEGIES
- PREVENTION: NOVEL AGENTS AND APPROACHES
- DRUG-RESISTANT/REFRACTORY CMV: IDENTIFICATION OF RESISTANCE AND ALGORITHMS FOR TREATMENT
- NEWER DRUGS AND APPROACHES FOR RESISTANT/REFRACTORY CMV
- ONGOING AND RECENTLY COMPLETED TRIALS
- CONCLUSIONS AND FUTURE DIRECTIONS
- ACKNOWLEDGMENTS
- FOOTNOTES
- REFERENCES
- Author Bios
- Figures & Data
- Info & Metrics